Parenteral Medicines Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 28-06-2024
- Paid Up Capital ₹ 0.50 M
as on 28-06-2024
- Company Age 29 Year, 20 Days
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 547.55 Cr
as on 28-06-2024
- Satisfied Charges ₹ 14.48 Cr
as on 28-06-2024
- Revenue %
(FY 2021)
- Profit 3.48%
(FY 2021)
- Ebitda 3.91%
(FY 2021)
- Net Worth -36.34%
(FY 2021)
- Total Assets -8.29%
(FY 2021)
About Parenteral Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹547.55 Cr. The company has closed loans amounting to ₹14.48 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shashi Garg, Alpana Gupta, and Aruna Gupta serve as directors at the Company.
- CIN/LLPIN
U24230MH1995PLC094929
- Company No.
094929
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
01 Dec 1995
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Parenteral Medicines?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shashi Garg  | Director | Current | |
| Alpana Gupta | Director | 09-Feb-2016 | Current |
| Aruna Gupta | Director | Current |
Financial Performance of Parenteral Medicines.
Parenteral Medicines Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 3.48% increase in profit. The company's net worth observed a substantial decline by a decrease of 36.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parenteral Medicines?
In 2021, Parenteral Medicines had a promoter holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rajratan Exports Private LimitedActive 29 years 5 monthsShashi Garg, Alpana Gupta and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 21 Dec 2012 | ₹547.55 Cr | Open |
Lakshmi Vilas Bank Limited Creation Date: 31 Mar 2015 | ₹14.00 Cr | Satisfied |
State Bank Of India Creation Date: 22 Dec 2005 | ₹4.80 M | Satisfied |
How Many Employees Work at Parenteral Medicines?
Unlock and access historical data on people associated with Parenteral Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parenteral Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parenteral Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
